Uncategorized

Introduction to Tirzepatide Tirzepatide, a novel drug, has garnered significant attention in the medical landscape due to its promising profile in managing type 2 diabetes and possibly obesity. Developed by Eli Lilly and Company, this dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist represents a significant advancement in metabolic disease treatment. Mechanism […]

Here’s an overview: Introduction to Semaglutide and Its Origins Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was developed to manage type 2 diabetes and obesity. Derived from the natural human incretin hormone GLP-1, semaglutide: The initial aim of semaglutide’s development was to improve glycemic control, reduce body weight, and mitigate cardiovascular risks associated with diabetes.